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Abstract: Chronic neuropathic pain that may arise from various nerve injuries or insults 
remains notoriously difficult to manage. The neuronal isoform of the enzyme nitric oxide 
synthase (nNOS) has been shown to be involved in the spinal transmission of nociception in 
animal models of chronic pain. The aim of this study is to evaluate the effect of single dose and 
repeated administration of a selective nNOS inhibitor. Rats were unilaterally implanted with a 
2-mm polyethylene cuff around the sciatic nerve. Paw withdrawal thresholds were measured using 
von Frey filament stimulation. Rats were given 10, 20, or 30 mg/kg of 7-nitroindazole (7-NI), 
or vehicle, on days 2, 5, and 7 after model induction, respectively. Paw withdrawal thresholds 
were measured before and at 30 and 60 min after injection. 7-NI significantly increased paw 
withdrawal thresholds at 60 min at the 20 and 30 mg/kg dosages. In the second part of this study, 
rats were given 20 mg/kg 7-NI daily for five days starting immediately after cuff implantation 
(days 0 to 4), and the cuff was removed on day 4. Withdrawal thresholds were measured intermit-
tently over a 24-day observation period. No differences in withdrawal thresholds were observed 
between drug and vehicle-treated rats. Therefore, early and repeated administration of 7-NI did 
not affect the development or progression of the model. In conclusion, inhibition of nNOS had 
an analgesic but not a pre-emptive effect in this model of peripheral neuropathic pain.
Keywords: neuronal nitric oxide synthase, nitric oxide, 7-nitroindazole, neuropathic pain, 
peripheral nerve injury, nociception
Introduction
Physiological pain clearly serves an important protective function. However, when 
pain lasts more than 3 months, it is classified as chronic pain, and pathological 
  mechanisms may be involved. The International Association for the Study of Pain 
(IASP) has recently refined the definition of neuropathic pain as “pain arising as 
a direct consequence of a lesion or disease affecting the somatosensory system”.1 
Therefore, neuropathic pain may result from a range of causes, including trauma, 
infection, ischemia, and toxicity. Nitric oxide has been identified as one of the many 
agents involved in neuropathic pain.
Nitric oxide is a gaseous neurotransmitter in the central nervous system (CNS) and 
the peripheral nervous system (PNS), and is able to diffuse across the cell membrane.2 
Nitric oxide is involved in several physiological processes including smooth muscle 
relaxation, inflammation, vasodilation, neurogenesis, synaptic plasticity, long-term 
potentiation, and nociceptive transmission.2,3 The enzyme nitric oxide synthase (NOS) Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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catalyzes the production of nitric oxide from L-arginine 
and oxygen, and different isoforms of the enzyme exist in 
different tissues. Nitric oxide is constitutively produced by 
neuronal NOS (nNOS) and endothelial NOS (eNOS) in a 
calcium-dependent manner, and is also formed by an induc-
ible form of the enzyme (iNOS), which may have detrimental 
effects on the cell.2–4 Neuronal NOS is found in both the 
CNS and PNS.
Neuronal NOS has been specifically localized to spinal 
cord dorsal horn neurons and dorsal root ganglia (DRG) 
cells, and is upregulated in conditions of inflammatory and 
neurogenic pain.3–5 Synthesis of nitric oxide in the nocicep-
tive pathway is thought to be the result of activation of the 
N-methyl-D-aspartate (NMDA) receptor. Activation of 
peripheral nociceptive neurons results in the presynaptic 
release of glutamate, as well as various neuromodulators. 
Sufficient depolarization of the postsynaptic membrane 
will activate NMDA receptors allowing an influx of Ca2+ 
into the dorsal horn neurons, which leads to, among other 
events, activation of nNOS and synthesis of nitric oxide.2 
Nitric oxide may act at the postsynaptic neuron, or act as a 
retrograde transmitter at the presynaptic neuron, as well as 
interneurons and glial cells.2 Nitric oxide can facilitate noci-
ceptive transmission through its downstream targets.4
Several lines of evidence have shown that the synthesis of 
nitric oxide may play an important role in neuropathic pain 
following nerve injury. Experimentally it has been shown that 
chronic constriction injury (CCI) causes increased nNOS-
immunoreactivity in the L4 to L6 DRG cells and dorsal horn 
neurons ipsilateral to nerve injury,6 and also in the sciatic 
nerve epineurium.7 Increases in nNOS protein and mRNA 
were also observed following peripheral axotomy in the 
DRG and trigeminal ganglion.8 An electrophysiological study 
found that administration of the nonselective NOS inhibi-
tor Nω-nitro-L-arginine methyl ester (L-NAME) attenuated 
ongoing discharges in the DRG in a sciatic nerve axotomy 
model.9 Finally, behavioral studies have shown that L-NAME 
and selective nNOS inhibitors relieve pain hypersensitivity in 
various nerve injury models,10–12 while nitric oxide precursors 
and donors enhance hypersensitivity.13
The objective of the present study is to determine whether 
nitric oxide is involved in the maintenance or the develop-
ment of a modified version of the sciatic cuff model14 of 
neuropathic pain. The immediate effect of nNOS inhibition 
was assessed in cuff-implanted rats. Also, the effect of early 
and repeated administration of the nNOS inhibitor on the 
development of the model was assessed over 24 days.
Materials and methods
Animals
Male Sprague-Dawley rats (Charles River, Quebec, Canada) 
were housed in pairs and maintained on a 12-hour light 
cycle, with food and water available ad libitum. All proce-
dures complied with the Guidelines for the care and use of 
experimental animals, Volumes I and II, of the Canadian 
Council on Animal Care. All procedures were also approved 
by the Animal Research Ethics Board (McMaster University, 
Hamilton, Ontario, Canada).
Drug
For the single dose study, 7-nitroindazole (7-NI; Lancaster Syn-
thesis, Windham, NH) was dissolved in 75% dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, St. Louis, MO) in saline, and given 
at dosages of 10, 20, or 30 mg/kg. 7-NI and the vehicle were 
administered intraperitoneally (IP) at a volume of 0.1 mL/100 g 
body weight. For the repeated   administration study, 7-NI was 
dissolved in DMSO, and given at a dosage of 20 mg/kg. 7-NI 
and the vehicle were administered IP at half the injection vol-
ume above (0.05 mL/100 g body weight). The drug solution 
was prepared fresh on each day before injection.
surgical preparations
cuff implantation
The method of sciatic nerve constriction is based on that 
described by Mosconi and Kruger.14 Rats were anesthetized 
with a combination of ketamine (Ketalean; 5 mg/100 g; Bime-
da-MTC Animal Health Inc, Cambridge, Ontario, Canada), 
xylazine (Rompun; 0.5 mg/100 g; Bayer HealthCare, Toronto, 
Ontario, Canada), and acepromazine (Atravet; 0.1 mg/100 g; 
Ayerst Veterinary Laboratories, Guelph, Ontario, Canada) by 
IP injection. The left sciatic nerve was exposed after blunt 
dissection of overlying muscle and freed from surrounding 
tissue. A cuff made of a 2 mm segment of polyethylene 
(PE-90) tubing (Intramedic PE-90, Clay Adams, Division 
of Becton Dickinson, Parsippany, NJ) slit longitudinally was 
fitted around the nerve. Subsequently the muscle was sutured, 
and the skin closed using suture clips. Antibiotic ointment 
(Furacin; nitrofurazone 0.2%;   Vetoquinol N-A Inc, Lavaltrie, 
Quebec, Canada) was applied over the wound, and 0.03 mL 
of antibiotic (Novo-Trimel; 40 mg/mL sulfamethoxazole 
and 8 mg/mL trimethoprim; Novopharm, Toronto, Ontario, 
Canada) was injected subcutaneously (SC). Animals were 
given 1 mL saline SC, ocular lubricant, and placed under a 
heating lamp until they recovered from the anesthetic and 
then returned to their home cage.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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cuff removal
Animals were anesthetized and the sciatic nerve was exposed 
as described above. The cuff was located and removed using 
a fine forceps while care was taken not to damage the nerve. 
The muscle and skin were sutured as described above and 
the same postsurgical care procedures were followed. Cuff 
removal was performed on day 4 after implantation.
Behavioral test
Paw withdrawal thresholds
The testing chamber consisted of a 30 × 30 × 30 cm 
  Plexiglas box with a clear Plexiglas floor. This floor con-
tained 0.5 cm diameter holes that were spaced 1.5 cm apart, 
and was positioned over a mirror tilted 45° which allowed an 
unobstructed view of the rat paws. Animals were placed in the 
testing chamber and allowed to acclimatize for 30 min prior 
to testing with their cage mate. Von Frey filaments (Stoelting 
Co, IL) were applied to the soft tissue of the plantar surface 
of the hind paw to determine the withdrawal threshold. The 
first filament applied corresponded to a force of 2 g. Each 
filament tested was applied three times, at 3 s intervals; a paw 
withdrawal to any of these three applications was considered 
a positive response, while no response to any application 
was considered a negative response. If a negative response 
was observed, a filament exerting greater force was applied, 
and if a positive response was observed, a filament of lesser 
force was used next. A 50% response threshold was calculated 
according to the response pattern observed.15 The maximum 
score possible was 15 g, and the minimum was 0.25 g.
Testing after a single dose of 7-ni
To determine if administration of 7-NI has any immediate 
effects on mechanical withdrawal thresholds in cuff-
implanted rats, von Frey readings were taken prior to drug 
administration, and at 30 and 60 min after drug administration. 
12 rats were implanted with a sciatic nerve cuff on day 0 
(n = 6 for the 7-NI treatment group; n = 6 for the vehicle 
group). The testing schedule was as follows: 10 mg/kg 7-NI 
on day 2; 20 mg/kg 7-NI on day 5; and 30 mg/kg 7-NI on 
day 7 post cuff-implantation. Seventy-five percent DMSO 
was given to the vehicle groups. Rats weighed 150–175 g at 
the time of model induction.
Repeated administration of 7-ni  
with cuff removal
To determine if repeated administration of 7-NI has any 
cumulative effects on mechanical withdrawal thresholds in 
the 4-day cuff removal model, rats were given 20 mg/kg 7-NI 
(the optimal dose as determined by the single dose experi-
ments) daily starting on the day of cuff implantation surgery 
until day 4 (for a total of 5 injections). Injections were given 
after von Frey testing. DMSO was given to the vehicle group 
(0.05 mL/100 g body weight). Rats weighed 230–260 g at 
the time of model induction.
statistics
Data from the single dose experiments were analyzed using 
a repeated-measures one-way analysis of variance (ANOVA) 
with the Bonferroni test with all pair-wise comparisons for 
post hoc analyses. Data from the repeated   administration 
experiment were analyzed with a repeated-measures,   two-way 
ANOVA (treatment and day) with Bonferroni post hoc 
comparisons. Analyses were performed using Prism 4.03, 
GraphPad Software, Inc, (San Diego, CA).
Results
single dose
Three doses of 7-nitroindazole (7-NI; 10, 20, and 30 mg/kg) 
were given to rats with a permanent cuff, and paw withdrawal 
thresholds were measured using von Frey filaments at 
30 and 60 min after drug administration. On day 2 after 
cuff implantation, the 10 mg/kg dose of 7-NI (IP, n = 6) 
did not have a statistically significant effect on ipsilateral 
(Figure 1) or contralateral (data not shown) withdrawal 
thresholds. Vehicle administration was without effect (n = 6; 
Figure 1). On day 5, administration of 20 mg/kg 7-NI (IP, 
n = 6)   significantly increased withdrawal thresholds at 
60 min (*P , 0.05   compared to pre-drug values; Figure 2). 
No significant effects were observed in the contralateral paw 
at this dose (data not shown). Vehicle administration was 
without effect (n = 6; Figure 2). Administration of 30 mg/kg 
7-NI (IP, n = 6) to rats on day 7 after cuff implantation 
significantly increased ipsilateral withdrawal thresholds at 
60 min (**P , 0.01; Figure 3). No effects were observed 
on the contralateral side (data not shown), and the vehicle 
was without effect (n = 6; Figure 3). It was noted that the 
30 mg/kg dose (and 75 mg/kg dose; data not shown) caused 
sedation and motor impairment, therefore, the 20 mg/kg dose 
was chosen for the repeated administration experiment.
To rule out the possibility of cumulative effects of 7-NI 
in this study design, a repeated-measures, one-way ANOVA 
was performed to compare the pre-drug baselines for each 
test day (2, 5, and 7). There were no differences between pre-
7-NI (or pre-vehicle) values. Also, unpaired t-tests comparing Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Figure 1 single dose administration of 7-nitroindazole (7-ni; 10 mg/kg; iP, n = 6) to rats with a sciatic nerve cuff did not have an effect on the ipsilateral paw withdrawal 
thresholds at 30 min and 60 min after injection. Vehicle administration also did not have an effect at 30 min or 60 min (n = 6). Testing was done on day 2 after cuff 
implantation.
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Figure 2 single dose administration of 7-nitroindazole (7-ni; 20 mg/kg; iP, n = 6) to rats with a sciatic nerve cuff (day 5) significantly increased ipsilateral paw withdrawal 
thresholds at 60 min (*P , 0.05 compared to pre-drug values). Vehicle administration did not affect ipsilateral paw withdrawal thresholds at 30 min or 60 min (n = 6).
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Figure 3 single dose administration of 7-nitroindazole (7-ni; 30 mg/kg; iP, n = 6) to rats with a sciatic nerve cuff (day 7) significantly increased ipsilateral paw withdrawal 
thresholds at 60 min (**P , 0.01 compared to pre-drug values). Vehicle administration did not affect ipsilateral paw withdrawal thresholds at 30 min or 60 min (n = 6).Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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pre-7-NI versus pre-vehicle baselines were run for each test 
day, and no differences were found.
Repeated administration and cuff removal
In order to determine if repeated 7-NI administration would 
have an effect on long-term withdrawal thresholds, rats were 
implanted with a sciatic nerve cuff that was removed on day 4. 
Rats were given 7-NI or vehicle on days 0 to 4.   Previous 
studies from this laboratory have shown that there is a par-
tial recovery with a 4-day cuff compared to a permanently 
implanted cuff. There were no differences in withdrawal 
thresholds between rats given 7-NI (20 mg/kg, IP, n = 5) or 
vehicle (n = 5) on any of the days tested, over the 24-day 
observation period (Figure 4).
Discussion
The objective of this study was to determine the effect of 
the inhibition of neuronal nitric oxide synthase (nNOS), the 
enzyme responsible for the generation of the neurotransmitter 
nitric oxide in the nervous system, in a model of peripheral 
neuropathy. The effect of the selective nNOS inhibitor 
7-nitroindazole (7-NI) was determined in the sciatic cuff 
model of neuropathic pain. 7-NI increased paw withdrawal 
thresholds at 60 min after administration, in a dose-dependent 
manner. Therefore, nNOS inhibition had an analgesic effect 
in this model. The effect of repeated 7-NI administration 
on the development of the model was also tested when the 
cuff was removed on day 4. In previous studies (data not 
shown), it was shown that cuff removal on day 4 causes partial 
recovery of the model after several weeks. Therefore, 7-NI 
was given starting immediately after cuff implantation and 
continued daily until cuff removal on day 4, to determine if 
recovery would be accelerated or enhanced. Since no effect 
was observed on model development or progression, it is 
concluded that 7-NI did not have a preemptive or cumulative 
effect in this model.
The effects of single dose 7-NI observed here are in 
  agreement with previous studies of NOS inhibition after nerve 
injury. The nonselective NOS inhibitor   Nω-nitro-L-arginine 
methyl ester (L-NAME) attenuated thermal hyperalgesia for 
2 h when given intrathecally to rats with chronic constriction 
injury (CCI model; loose ligation) of the sciatic nerve.16 In 
the L5/L6 spinal nerve ligation model, IP L-NAME decreased 
mechanical hyperalgesia, cold allodynia, and signs of ongo-
ing pain.17 In a rat model of spinal cord ischemia, L-NAME, 
and the selective nNOS inhibitors 6-NI (6-nitroindazole) 
and 7-NI given IP decreased the vocalization threshold in 
response to mechanical stimulation of the skin innervated 
by the injured spinal cord segment.10 7-NI administered by 
lumbar puncture to rats with sciatic nerve transection also 
decreased mechanical hyperalgesia and allodynia.12 This 
study also showed nerve-injured rats had increased expres-
sion of nNOS in the spinal cord as shown by immunohis-
tochemistry, real-time polymerase chain reaction (PCR) and 
immunoblotting. In the CCI model, 10 and 30 mg/kg 7-NI, 
IP, but not 3 mg/kg, were effective in decreasing mechanical 
allodynia, thermal hyperalgesia, and cold allodynia.13 The 
conclusion of each of these studies is that the production 
of nitric oxide is involved in the maintenance of pain-like 
behaviors following nerve injury.
Studies on the effects of repeated treatment with NOS 
inhibitors are scarce. A study that also used the sciatic-cuff 
model tested the effect of intrathecal L-NAME on heat 
hyperalgesia and cold allodynia when given prior to model 
induction and daily until day 4.18 L-NAME decreased thermal 
sensitivity for up to 30 days post-cuff compared to controls. 
Although the experimental designs of this study and the 
present study are very similar, the use of a nonselective 
NOS inhibitor and the measurement of thermal sensitivity 
are two key differences that may account for the conflicting 
results. Another study used the L5/L6 spinal nerve ligation 
model, and mechanical allodynia was assessed using von 
Frey filament stimulation according to the same methods used 
in the present study.19 They found that a single IP L-NAME 
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Figure 4 Rats were implanted with a sciatic nerve cuff on day 0, and the cuff was 
removed on day 4. Rats were given either 7-nitroindazole (7-ni; 20 mg/kg; iP, n = 5; 
closed circles) or vehicle (n = 5; open circles) on days 0 to 4. There were no 
differences in mechanical withdrawal thresholds between the two groups on any 
of the days tested.Journal of Pain Research
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injection given immediately before model   induction reduces 
mechanical allodynia for at least 14 days (the specific nNOS 
inhibitor LY 457963 did not have a preemptive analgesic 
effect). However, the preemptive effect of L-NAME was 
not reversible with L-arginine administration. Therefore 
the authors conclude that this effect is not due to NOS 
inhibition.19 The conclusion that NOS/nNOS inhibition is 
not involved in the development of the model may be in 
accord with the present study. However, these authors also 
report that the immediate analgesic (30 min to 2 h) effect of 
L-NAME is also not reversible by L-arginine, and therefore 
this effect is not likely due to nNOS inhibition either.19 They 
suggest that L-NAME may have additional mechanisms of 
action that may account for its analgesic effects (immediate 
and preemptive).
In summary, the effectiveness of the selective nNOS 
inhibitor 7-NI in reducing allodynia within 60 min indicates 
that nNOS activity is involved in the steady-state model of 
neuropathic pain. That early and repeated 7-NI administration 
was without a cumulative effect suggests that nNOS activity 
may not be critical to the development of long-term mechani-
cal hypersensitivity in this model of neuropathic pain.
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